Background: To date, no Brazilian registry has been designed to document the clinical practice regarding assistance to patients at high cardiovascular risk in a large representative sample of research centers, including public and private hospitals nationwide. Thus, this study will identify gaps in the incorporation of interventions with proven benefit in our area.
Introduction
Based on systematic reviews of observational evidence (studies of prevalence), the World Health Organization has provided consistent estimates of causes of death by sex and age, in countries and regions. Recent data show that cardiovascular diseases (CVD) are the leading cause of disability and mortality in both sexes, both in Brazil and in the world [1] [2] [3] . Additionally, this rapid growth in developing countries represents one of the most relevant public health issues today, where 80.0% of deaths from chronic diseases (mainly cardiovascular diseases) occur precisely in less privileged regions in the world [1] [2] [3] [4] [5] [6] . According to forecasts from the classic study Global Burden of Diseases, by Murray and Lopez 7 for the year 2020, there are indications that CVD will not only remain the leading cause of death, but will also represent the leading cause of disability, whereas Disability Adjusted Life Years (DALYs) attributable to CVD will increase to about 140 to 160 million, and the higher proportion will come from developing countries.
Within the current concept of cardiovascular prevention, more important than classifying an individual as having diabetes mellitus (DM), hypertension (HTN) or dyslipidemia (DLP), it is to characterize them in terms of cardiovascular risk 3 . Prevention based on the concept of cardiovascular risk means guiding prevention efforts not for the risks attributable to the increase of isolated factors, such as blood pressure or cholesterol, but the sum of risk due to multiple factors, estimated by overall absolute risk in each individual.
To date, no Brazilian registry has been designed to document the clinical practice regarding assistance to patients at high cardiovascular risk in a large representative sample of research centers, including public and private hospitals nationwide. In this sense, knowing the current clinical practice in the country will identify gaps in the incorporation of evidence-based interventions.
In addition, following up major cardiovascular events, though to a lesser term, it is necessary for the understanding and development of projects for improvement of quality of care in order to reduce such events.
Methods
The registry represents a documentation project on current clinical practice of caring for patients at high cardiovascular risk in centers across all Brazilian regions, including public and private hospitals and basic health care units.
Design
Cross sectional observational study (registry) intended to document the clinical practice of managing patients at high cardiovascular risk in the country. Additionally, there will be longitudinal follow-up of these patients in 6 to 12 months.
Eligibility and inclusion criteria
The eligibility of patients for inclusion in this study is described in Box 1.
Exclusion criteria
• Refusal to provide Informed Consent (IC);
• Neurocognitive or psychiatric condition that prevents obtaining reliable clinical data (as judged by investigators);
• Life expectancy of less than 6 months (e.g., malignant metastatic neoplasm or others as clinically judged by investigators).
Sample characteristics and operational flowchart
Data will be collected from 2,305 patients at high cardiovascular risk, after consent, as identified in Public Hospitals and Private Hospitals and Basic Health Units (BHU). Non-probability sampling will be used, including consecutive patients who meet eligibility criteria. Figure 1 shows the flowchart for the analysis and inclusion of patients for participation in this registry.
Details of clinical visits
Index visit -measuring the inclusion and exclusion criteria, demographics, past medical and surgical history, physical examination, approach to the patient about non- pharmacological measures to reduce cardiovascular risk and adherence to drug therapies based on evidence.
Clinical follow-up visit at 6 and 12 months -checking adherence to evidence-based therapies and the occurrence of major cardiovascular events.
Primary outcome
Measuring the proportion of patients receiving interventions with proven benefits demonstrated by the indicators defined (e.g., aspirin, statins, ACE inhibitors), their impact on adherence and late outcomes.
Secondary outcomes
The following events will be recorded:
• Proportion of hypertensive patients with controlled levels according to SBC guidelines;
• Proportion of patients with target levels of LDL according to SBC guidelines;
• Proportion of patients receiving recommendations for quit smoking, physical activity and nutrition guidelines;
• Occurrence of serious cardiovascular events (myocardial infarction, stroke, fatal and non fatal cardiac arrest and cardiovascular mortality) within 12 months, tested in combination and alone.
Sample calculation
In order to detect a proportion of 40% for the occurrence of the primary outcome, considering a sampling error of 2%, an alpha of 5% and a statistical power of 90%, 2,305 patients must be included. This sample size is sufficient to meet the primary objectives of the study, which is feasible within the first year of recruitment.
Statistical analysis
Quantitative variables are expressed as mean and standard deviation in the presence of normal or median distribution and interquartile range in the presence of asymmetric distribution. Qualitative variables are presented in absolute frequencies (number of patients) and relative frequencies (percentage).
The primary and secondary outcomes will be described by an overall percentage, considering all centers, and the percentage prescribed in each center. Also, these will be expressed by means of proportions and their confidence intervals of 95%. Where there is great variability in prescription, a weighted average variance at each center will be generated.
For regression models, we will report the odds ratio (logistic regression) or hazard ratio [HR] (for the regression of Cox proportional hazards), the corresponding standard error, the confidence intervals of 95% and p-values. We will report the p-values up to three decimal places with p-values below 0.001 reported as p < 0.001. In all tests, we will use the two-tailed alpha significance level = 0.05. An examination of residues will provide an assessment of model assumptions for the regression analyses. The Goodness-of-fit test for the models will be performed using appropriate Hosmer-Lemeshov tests. We will carry out all analyses using Stata, version 10.0 (StataCorp. 2007. College Station, TX: StataCorp LP).
Financing
This Registry is owned by the Brazilian Society of Cardiology using funds dedicated to this purpose for its implementation.
The Instituto de Ensino e Pesquisa do Hospital do Coração de
São Paulo (HCor/ASS) was contracted to implement this registry, under the coordination of the Brazilian Society of Cardiology. The steering committee of the registry is described later in this article.
Quality control and data management
For the quality control of study data the following strategies will be used: initial classroom training, e-CRF and central check of data and tutoring.
Ethical considerations
The 
Publishing policy
All presentations of the study and/or publication of findings will be based on clear evidence verified and validated in order to ensure accurate results. Details about the responsibility and sequence of these presentations and/or publications will be defined with the Brazilian Society of Cardiology.
The authorship of publication of the main conclusions of this study will be based the contributions from the study centers in general. All participants in the registry (investigators and committee members) should make an advance delegation of authority to the Brazilian Society of Cardiology and the 
